P2RY12 and atrial fibrillation: The RE-DUAL PCI study was the second full-scale RCT regarding the topic (Figure 1) (6), and it compared two dabigatran (110 mg or 150 mg bid)-based DAT regimens plus a P2Y12 inhibitor with a standard TAT containing VKA and DAPT in 2,725 AF patients undergoing PCI (18).